Abstract
Compromised muscle mitochondrial metabolism is a hallmark of peripheral arterial disease, especially in patients with the most severe clinical manifestation - critical limb ischemia (CLI). We asked whether inflexibility in metabolism is critical for the development of myopathy in ischemic limb muscles. Using Polg mtDNA mutator (D257A) mice, we reveal remarkable protection from hind limb ischemia (HLI) due to a unique and beneficial adaptive enhancement of glycolytic metabolism and elevated ischemic muscle PFKFB3. Similar to the relationship between mitochondria from CLI and claudicating patient muscles, BALB/c muscle mitochondria are uniquely dysfunctional after HLI onset as compared with the C57BL/6 (BL6) parental strain. AAV-mediated overexpression of PFKFB3 in BALB/c limb muscles improved muscle contractile function and limb blood flow following HLI. Enrichment analysis of RNA sequencing data on muscle from CLI patients revealed a unique deficit in the glucose metabolism Reactome. Muscles from these patients express lower PFKFB3 protein, and their muscle progenitor cells possess decreased glycolytic flux capacity in vitro. Here, we show supplementary glycolytic flux as sufficient to protect against ischemic myopathy in instances where reduced blood flow-related mitochondrial function is compromised preclinically. Additionally, our data reveal reduced glycolytic flux as a common characteristic of the failing CLI patient limb skeletal muscle.
Introduction
Peripheral Arterial Disease (PAD) affects millions globally. Its most severe manifestation, Critical Limb Ischemia (CLI), often leads to muscle necrosis and amputation. While clinical interventions typically focus on restoring blood flow ("plumbing"), many patients continue to suffer from severe muscle wasting (myopathy) even after successful revascularization. This suggests a fundamental biological bottleneck: metabolic inflexibility.
Muscle cells primarily rely on mitochondria for ATP production. In ischemic conditions, oxygen deprivation causes mitochondrial failure. Without a rapid pivot to non-oxygen-dependent energy production (glycolysis), cellular energy levels plummet, leading to cell death. This study investigates whether boosting the glycolytic "backup system" can protect ischemic limbs when mitochondrial function is compromised.
Methods
The study utilized a multi-pronged approach combining transgenic mouse models, human clinical samples, and gene therapy:
- Animal Models: Researchers compared "protected" Polg mtDNA mutator (D257A) mice, which accumulate mitochondrial mutations, against "susceptible" BALB/c mice that mimic the human CLI phenotype.
- Gene Therapy: An Adeno-Associated Virus (AAV9) vector was used to overexpress PFKFB3 (a master regulator of glycolysis) in the limb muscles of susceptible mice.
- Metabolic and Transcriptomic Analysis: Seahorse XF analyzers measured glycolytic flux (ECAR) in mouse and human primary muscle cells. RNA-seq was performed on mouse tissues and human CLI biopsies (GSE114070) to identify pathway-level deficits.
Results
The Mitochondrial Paradox in D257A Mice
Surprisingly, D257A mice, despite having "fragile" mitochondria, showed remarkable resistance to ischemic injury. The ischemic lesion area in these mice was only 8.2%, compared to 88.5% in wild-type controls. This protection stems from a beneficial metabolic adaptation: lifelong mitochondrial dysfunction "pre-conditioned" these mice to rely more heavily on glycolysis, making them resilient to sudden oxygen loss.
PFKFB3 as a Therapeutic Target
The study identified PFKFB3 as the key mediator of this glycolytic rescue. Delivering AAV-PFKFB3 to susceptible BALB/c mice significantly improved limb perfusion and rescued muscle contractile force, which was otherwise undetectable in untreated ischemic controls. Conversely, inhibiting PFKFB3 with a small molecule (PFK15) abolished the protection in D257A mice, proving the enzyme's necessity.
Human Clinical Relevance
Analysis of human CLI biopsies revealed a unique deficit in the "Glucose Metabolism Reactome." Unlike the resistant mouse model, human CLI muscle cells fail to ramp up glycolysis during crisis, exhibiting significantly lower basal and maximal glycolytic flux compared to healthy controls. This "metabolic exhaustion" likely contributes to the severe myopathy seen in patients.
Discussion and Future Directions
These findings suggest that limb salvage requires a shift in focus from purely vascular restoration to "metabolic rescue." By overexpressing PFKFB3, muscle tissue can be kept alive during critical windows of low perfusion.
However, several questions remain. The use of a ubiquitous promoter in the AAV model means PFKFB3 was upregulated in multiple cell types; future research must distinguish the relative contributions of improved muscle metabolism versus enhanced angiogenesis. Additionally, the efficacy of this gene therapy in chronic ischemia, where fibrosis and inflammation are prevalent, requires further investigation. Translating these findings to clinical trials will involve overcoming hurdles in delivery efficiency and managing potential systemic effects of upregulated glycolysis.
Summary updated